Nephros (NASDAQ:NEPH) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Nephros (NASDAQ:NEPHGet Rating) from a hold rating to a sell rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “

Several other research firms have also commented on NEPH. B. Riley dropped their price objective on shares of Nephros from $8.00 to $5.25 in a research note on Thursday, May 5th. Benchmark cut shares of Nephros from a buy rating to a hold rating in a research report on Monday, May 9th.

Nephros stock opened at $2.05 on Wednesday. Nephros has a 1 year low of $2.00 and a 1 year high of $11.67. The firm’s 50 day moving average price is $4.00 and its 200-day moving average price is $5.29.

Nephros (NASDAQ:NEPHGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). Nephros had a negative net margin of 53.75% and a negative return on equity of 36.24%. During the same quarter in the previous year, the business earned ($0.06) earnings per share. As a group, analysts anticipate that Nephros will post -0.58 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Wexford Capital LP acquired a new stake in shares of Nephros in the fourth quarter valued at about $646,532,000. Renaissance Technologies LLC acquired a new stake in shares of Nephros in the first quarter valued at about $89,000. Bard Associates Inc. grew its position in shares of Nephros by 6.0% in the first quarter. Bard Associates Inc. now owns 246,408 shares of the company’s stock valued at $1,084,000 after purchasing an additional 13,900 shares during the period. Morgan Stanley boosted its position in Nephros by 186.3% during the third quarter. Morgan Stanley now owns 13,837 shares of the company’s stock worth $121,000 after acquiring an additional 9,004 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership boosted its position in Nephros by 56.0% during the first quarter. Elkhorn Partners Limited Partnership now owns 23,712 shares of the company’s stock worth $104,000 after acquiring an additional 8,512 shares during the last quarter. Institutional investors own 55.55% of the company’s stock.

About Nephros (Get Rating)

Nephros, Inc develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Read More

Get a free copy of the Zacks research report on Nephros (NEPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.